Daiichi Sankyo, MSD withdraw cancer drug application

BLA Filingifinatamab deruxtecanNegative

AI Analysis

Summary

Daiichi Sankyo and Merck & Co have voluntarily withdrawn their biologics license application for ifinatamab deruxtecan, a cancer drug candidate for treating extensive-stage small cell lung cancer.

Outcome Details

Voluntary withdrawal of biologics license application

Importance:7/10

Sentiment:

-0.80

BLA withdrawaloncologylung cancerpartnershipregulatory setback

Related Companies

$DSKYF $MRK

Read the original article

Published by Pharmaceutical Technology on September 28, 2026 8:50 AM

Read Original